Literature DB >> 17989149

Induced sputum in the very young: a new key to infection and inflammation.

Huda Mussaffi1, Elizabeth M Fireman, Meir Mei-Zahav, Dario Prais, Hannah Blau.   

Abstract

BACKGROUND: Chronic inflammation and infection in patients with cystic fibrosis (CF) and other lung diseases begin early, making noninvasive diagnostic techniques vital. As induced sputum (IS) testing is useful in older patients, we investigated its adaptation to young nonexpectorating children.
METHODS: Following the inhalation of a 4.5% saline solution, sputum was collected by nasopharyngeal or oropharyngeal suction for culture and testing for inflammatory markers, with paired preceding oropharyngeal cough swabs (OCSs) in a subgroup. Specimens from 48 IS procedures (46 successful) in 20 CF children (median age, 3 years) were compared with 8 specimens from 8 non-CF pulmonary patients (median age, 4.5 years).
RESULTS: The procedure was safe, with arterial oxygen saturation remaining at > or = 96%. Cultures from 14 of 46 CF patients (30%) grew Pseudomonas aeruginosa, whereas cultures from 19 of 46 CF patients (41%) had no growth. Cultures from seven of eight non-CF subjects grew bacteria, but none were P aeruginosa. Comparing 29 paired IS and OCS samples, 11 and 5 samples, respectively, cultured P aeruginosa (not significant), whereas 12 and 21 samples, respectively, had no growth (p = 0.02). A correlation was found between the independent inflammatory markers NE and both interleukin (IL)-8 (r = 0.85; p < 0.001) and the percentage of neutrophils (r = 0.35; p < 0.05), confirming the validity of IS samples in evaluating early airway disease. IL-8 levels also increased with age (r = 0.41; p < 0.05). Inflammation was similar in CF and non-CF subjects.
CONCLUSIONS: IS testing in the young is feasible, safe, and clinically useful, and could serve as an outcome measure for new therapies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17989149     DOI: 10.1378/chest.07-2259

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

1.  Sputum induction improves detection of pathogens in children with cystic fibrosis.

Authors:  Jordana E Hoppe; Elinor Towler; Brandie D Wagner; Frank J Accurso; Scott D Sagel; Edith T Zemanick
Journal:  Pediatr Pulmonol       Date:  2015-01-07

2.  Determining cystic fibrosis-affected lung microbiology: comparison of spontaneous and serially induced sputum samples by use of terminal restriction fragment length polymorphism profiling.

Authors:  Geraint B Rogers; Stuart Skelton; David J Serisier; Christopher J van der Gast; Kenneth D Bruce
Journal:  J Clin Microbiol       Date:  2009-11-11       Impact factor: 5.948

Review 3.  Best practices in the treatment of early cystic fibrosis lung disease.

Authors:  Marijke Proesmans
Journal:  Ther Adv Respir Dis       Date:  2016-12-02       Impact factor: 4.031

4.  Induced sputum metabolomic profiles and oxidative stress are associated with chronic obstructive pulmonary disease (COPD) severity: potential use for predictive, preventive, and personalized medicine.

Authors:  Tao Zhu; Shanqun Li; Jiajia Wang; Chunfang Liu; Lei Gao; Yuzhen Zeng; Ruolin Mao; Bo Cui; Hong Ji; Zhihong Chen
Journal:  EPMA J       Date:  2020-11-04       Impact factor: 6.543

5.  Chest physiotherapy enhances detection of Pseudomonas aeruginosa in nonexpectorating children with cystic fibrosis.

Authors:  Christophe Marguet; Véronique Houdouin; Isabelle Pin; Philippe Reix; Frédéric Huet; Marie Mittaine; Sophie Ramel; Nathalie Wizla-Derambure; Michel Abely; Marie-Laure Dalphin; Michael Fayon; Tiphaine Bihouée; Muriel Le Bourgeois; Eric Deneuville; Harriet Corvol; Muriel Laurans; Laure Couderc; Evelyne Leroux; Ludovic Lémée
Journal:  ERJ Open Res       Date:  2021-03-08

6.  The CF-Sputum Induction Trial (CF-SpIT) to assess lower airway bacterial sampling in young children with cystic fibrosis: a prospective internally controlled interventional trial.

Authors:  Katherine Ronchetti; Jo-Dee Tame; Christopher Paisey; Lena P Thia; Iolo Doull; Robin Howe; Eshwar Mahenthiralingam; Julian T Forton
Journal:  Lancet Respir Med       Date:  2018-05-16       Impact factor: 30.700

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.